Ml-logo

TorreyPines Therapeutics Initiates Second Phase I Clinical Trial Of NGX426, A Potential Novel Oral T

CommentPost ArticleSave to My ArticlesList ArticlesRandom Article

Login is required to access that page

TORREYPINES THERAPEUTICS INITIATES SECOND PHASE I CLINICAL TRIAL OF NGX426, A POTENTIAL NOVEL ORAL T
Headache / Migraine News From Medical News Today, February 27, 2007

TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a second Phase I clinical trial of NGX426, a novel product candidate intended to treat chronic pain conditions such as migraine and neuropathic pain. NGX426 is an oral prodrug of tezampanel, the company's parenteral product candidate currently in a Phase IIb clinical trial for acute migraine. [click link for full article]

Comments

All information offered on this site is for educational purposes only and should not be construed as medical advice, diagnosis, or treatment.